FDA tells Prax­is it can't move in­to the clin­ic just yet for a rare epilep­sy drug

The FDA emailed Prax­is Pre­ci­sion Med­i­cines on Thurs­day to let the biotech know that its IND for a rare epilep­sy drug was placed on clin­i­cal hold.

“The clin­i­cal hold let­ter de­tail­ing the rea­sons for the hold is ex­pect­ed to be re­ceived from the FDA with­in 30 days of April 28, 2022,” the com­pa­ny said in a Fri­day morn­ing SEC fil­ing. Prax­is’ shares $PRAX were down near­ly 6% as of the open­ing bell Fri­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER